仲恩生醫7729.TW Overview
7729
仲恩生醫
-2.71%
(-0.03)
7729 Overall Performance
7729 AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
7729 Key Information
7729 Profile
Steminent Biotherapeutics, Inc. develops novel cellular therapeutics and engages in the research and development of new stem cell drugs. Its products include stemchymal, stemchymal therapeutic advantages and stemchymal application fields. The company was founded on December 18, 2007 and is headquartered in Taipei, Taiwan.
7729 FAQ
When is 7729's latest earnings report released?
The most recent financial report for 仲恩生醫 (7729) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7729's short-term business performance and financial health. For the latest updates on 7729's earnings releases, visit this page regularly.
How much cash does 7729 have?
At the end of the period, 仲恩生醫 (7729) held Total Cash and Cash Equivalents of 132.46M, accounting for 0.35 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.